Navigation Links
Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis

d A.G.G. Turpie, M.D., EXPERT's principal investigator and Professor of Medicine at McMaster University in Hamilton, Ontario. "We have long awaited a new generation of oral anticoagulants, and Portola has a promising compound with compelling drug characteristics resulting in consistent activity without the need for dose adjustment or monitoring. We will be closely following PRT054021 as it progresses into late-stage clinical trials."

Dr. Turpie discussed these data today in a poster session titled "Evaluation of the Factor Xa (fXA) Inhibitor, PRT054021 (PRT021), Against Enoxaparin in a Randomized Trial for the Prevention of Venous Thromboembolic Events after Total Knee Replacement (EXPERT)."

"We are very pleased by the EXPERT results, as PRT054021's clinical performance compared favorably to recent studies of enoxaparin for the prevention of VTE," said Dan Gretler, M.D., Portola's vice president of clinical and regulatory affairs. "We look forward to initiating our Phase III trials to further study our hypothesis that our oral, once-daily anticoagulant with superior pharmaceutical properties, including a relatively flat peak to trough concentration ratio, will lead to better outcomes for patients."

About EXPERT

EXPERT (Evaluation of the Factor Xa Inhibitor, PRT054021, against Enoxaparin in a Randomized Trial for the Prevention of Venous Thromboembolic Events after Unilateral Total Knee Replacement) randomized 215 U.S. and Canadian patients undergoing TKR surgery in a 2:2:1 ratio to receive 15 mg of PRT054021, 40 mg of PRT054021, or 30 mg of Lovenox(R) (enoxaparin) for 10-14 days. PRT054021 was given orally twice a day, and enoxaparin was given twice a day as a subcutaneous injection. The primary efficacy endpoint was the incidence of VTE through day 10-14 measured by venography. Safety endpoints included the incidence of major and clinically significant non-major bleeds through the day after venography. All efficacy and safety endpoints w
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/22/2014)... 22, 2014 Research and Markets ... Market by Equipment, by Reagent, by Application - Global ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals ... is one of the most important and widely used ... application segment of the cell culture market in 2013. ...
(Date:7/22/2014)... Mass. , July 22, 2014  Decision ... audited multiple sclerosis (MS) patients currently treated ... Tecfidera have ever experienced flushing and/or gastrointestinal ... Tecfidera-treated patients are currently experiencing these side ... the effective medical management of such events. ...
(Date:7/22/2014)... 2014 The number of people overdosing from ... day. Twenty-three percent of the workforce has misused prescription ... and Health, making opioid use a serious threat to ... at the correct dosage with a valid prescription, subtle ... National Safety Council released a guide for ...
Breaking Medicine Technology:Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 2Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 35 things employers should know about prescription painkiller use 25 things employers should know about prescription painkiller use 3
... Hospital today announced that revolutionary three-dimensional mammography imaging ... patient appointments at the Evergreen Breast Center, which ... Seattle area to offer the breakthrough screening and ... three-dimensional (3-D) digital imaging to create a complete ...
... Prescription drug spending growth slowed from an estimated ... according to new data released today by the Centers ... in Health Affairs. Researchers credit the slowdown in spending ... shifting medication use toward lower cost generic drugs. ...
Cached Medicine Technology:Evergreen Hospital Launches Revolutionary Breast Cancer Detection and Diagnostic Imaging Technology 2Evergreen Hospital Launches Revolutionary Breast Cancer Detection and Diagnostic Imaging Technology 3PCMA: Study Credits PBM Tools with Reducing Prescription Drug Spending Growth 2
(Date:7/22/2014)... City, OK (PRWEB) July 22, 2014 ... the launch of the newest component of its existing ... area hospital within the regional SSM Health Care of ... affiliate health centers that shares its services with an ... primary care centers across several states. As a forward-thinking ...
(Date:7/22/2014)... Provectus has started leading projects ... in addition to working with the long known OS ... as well as the creation of services for other ... requires special gadgets for work, leisure and business. Since ... healthcare, logistics, travelling, sports, education, science and other verticals. ...
(Date:7/22/2014)... 2014 It all started as a meeting ... find common ground. Willem de Liefde wanted to help family, ... lives or careers. , Willem wrote The Ego’s Echo for ... the surface of things. It is an invitation to go ... and commitment. , This book represents a breakthrough in the ...
(Date:7/22/2014)... The market for beauty products in the ... according to new industry reports. Women who seek out ... a new guide published at the Cherry News website. ... at http://cherrynews.com/best-nourishing-eye-serum . , This published guide is ... of the top skin improvement products on the market. ...
(Date:7/22/2014)... 2014 Mona Khan Company today announced ... 15th & 16th, 2014, at the Blanks Studio in ... nationally accredited Bollywood workout was launched in the San ... appealing Bollywood culture, Bombay Jam® is a dance-based total ... and designed with authentic Bollywood flavor. Instructor trainings have ...
Breaking Medicine News(10 mins):Health News:St. Anthony Hospital Expands Its Telemedicine Program with Telepsychiatry 2Health News:St. Anthony Hospital Expands Its Telemedicine Program with Telepsychiatry 3Health News:Provectus Announces Development for Google Glass and Wearables 2Health News:Willem de Liefde, Author and Management Expert, Releases New Guide for Understanding Friends, Family, Co-Workers and Ourselves 2Health News:Eye Serum Review for Women: New Guide Published Online by Top Review Website 2Health News:Mona Khan Company Announces Bombay Jam® Instructor Certification in Los Angeles in August 2014 2Health News:Mona Khan Company Announces Bombay Jam® Instructor Certification in Los Angeles in August 2014 3
... introduces Senator Daschle at his confirmation hearing to be ... WASHINGTON, Jan. 8 Bipartisan Policy Center (BPC) founding ... Health and Human Services Secretary, was introduced by fellow ... confirmation hearing today. The hearing was convened by the ...
... to condemn hurtful comments, study suggests , , THURSDAY, Jan. ... would react to racist acts, a new Canadian study says. ... in Toronto, still chose to partner for an experiment with ... their white peer made racist comments about the black person ...
... for Camp Courage at Mall of AmericaMINNEAPOLIS, Jan. 8 , WHO: ... off their talent in the 3rd annual Dance, ... event will be emceed by Tom ... Participants raise money through pledges to benefit Camp, ...
... in 2009 Continues Growth TrendNORTH HOLLYWOOD, Calif., Jan. 8 ... IPCM ), a leading national hospitalist physician group practice ... practice of Midwest Acute Care Consultants, Inc. (MACC) in ... the St. Louis market, where IPC has established a ...
... The Pew Charitable Trusts announced today that Erik ... safety programs, in its Health & Human Services Policy ... general counsel of the Senate Committee on Environment and ... environmental policy and consumer advocacy to Pew. "We are ...
... Cephalon, Inc . (Nasdaq: CEPH ) ... will present at the J.P. Morgan Healthcare Conference, to ... at approximately 4:00 p.m. Pacific Time (7 p.m. Eastern Time). ... section of the company,s website. The webcast will be archived ...
Cached Medicine News:Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Many Turn Blind Eye to Racism 2Health News:Dance With Courage to Benefit Camp Courage 2Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 3
... The BacT/Alert 3D Signature is ... microbial detection system that integrates blood, ... It is a powerful microbiology workstation ... for higher volume identification and where ...
... Vitek is a completely automated instrument that ... 2 - 6 hour same day turnaround), ... control module. It is used for bacterial ... urine screening and has a complete data ...
IDS Rapid One, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Medicine Products: